Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Multiple Myeloma 40Lymphoma, Large B-Cell, Diffuse 37Burkitt Lymphoma 34Lymphoma 31Leukemia, Myeloid, Acute 31Recurrence 28Lymphoma, Non-Hodgkin 28Breast Neoplasms 27Lymphoma, B-Cell 23Leukemia, Lymphocytic, Chronic, B-Cell 23Neoplasms 22Myelodysplastic Syndromes 22Lymphoma, Follicular 20Triple Negative Breast Neoplasms 18Hodgkin Disease 18Leukemia 17Melanoma 16Hematologic Neoplasms 16Ovarian Neoplasms 15Neuroblastoma 14Lymphoma, Mantle-Cell 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Leukemia, Biphenotypic, Acute 11Pancreatic Neoplasms 10Lymphoma, B-Cell, Marginal Zone 10Leukemia, Myelomonocytic, Chronic 10Sarcoma 9Osteosarcoma 9

Interventions

luspatercept 1ibrutinib 1fludarabine phosphate 1Rituximab 1Pluvicto 1Pharmacogenomic Testing 1Lenalidomide 1Epoetin Alfa 1Cyclophosphamide 1CT-P10 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia × Cyclophosphamide × 90 days × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡